Parkwalk

"Providing more care for people outside of hospital is not only beneficial for patients but is highly advantageous for healthcare providers,"

"From LEO satellite to terrestrial 5G deployments, the challenges of how to maximize the performance of the network, and in particular efficient use of energy and radio spectrum, are universal. Over the past few years, AccelerComm has continually demonstrated its position at the forefront of this technology, working with mobile operators, telecoms equipment vendors and the satellite industry to help supercharge communications. We’re thrilled to receive this backing from a range of industry-leading investors combined with the continued backing ongoing support of our existing shareholders and look forward to the company’s continued rapid growth and innovative development."

"Citi Markets uses its deep software expertise to move faster and be more competitive. We find value in Diffblue’s auto-generation of test cases, which helps drive test consistency and coverage of our software. This frees up developers to focus on delivering higher quality software, faster – and improves our developers’ experience,"

"The continued support from Parkwalk, Meltwind and BGF alongside new investment from Newable Ventures enables us to expand the reach of Censeo, helping more people who are struggling to find the right support for their mental health needs. We’re excited to grow our team, expand further across the NHS and demonstrate with our partners that our technology can make a substantial difference in the accuracy, consistency and efficiency of mental health assessments in a wide range of clinical settings."

"Our increasing desire for continually improving electronic device performance paired with the absolute necessity to reduce our power requirements, and hence carbon footprints, demands new technology solutions – next generation materials will be at the heart of this. At Paragraf we are proud to be leading the way, bringing the first 2D material, graphene, into the electronic product supply chain, through our first products, allowing its transformational, game changing properties and benefits to be harnessed."

"There are over three million dialysis patients worldwide and every year patients undergo nearly 650,000 surgical AVF creation procedures. However, these procedures take a long time to heal and are prone to failure. Our technology has the power to significantly improve the outcomes for dialysis patients, improving their quality of life and saving millions of pounds in the process. We are delighted to have the support of BGF and Parkwalk to help the business move forward with our clinical trials and ultimately roll-out this ground-breaking product to a global market."

"Our approach at Entia is to empower patients with greater freedom whilst also equipping healthcare professionals with the insights to make more informed and personalised clinical decisions."

"We’re excited to be backing a business that solves such a vitally important and growing issue – the preservation of data, now and in the future."

"Many researchers would like to get molecular binding data more conveniently and more frequently to guide them through a drug development project. HexagonFab aims to address this need with the Bolt. This investment will enable us to bring our game-changing product to the market. We look forward to the months ahead working closely with our lead customers,"

"We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates and we believe David and his team are doing just that. We are pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey."

"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."

"Diagnosing mental health issues correctly in primary care can be difficult, due to time constraints and the fact that mental health conditions can be masked by physical symptoms. Delays in diagnosing—or misdiagnosis—mean that it can take several years for an individual with depression to be correctly diagnosed. For bi-polar disorder the average delay is six to eight years. The consequence of this is that many people suffer unnecessarily from debilitating symptoms that could be successfully treated. It is clear that faster and earlier diagnosis followed by the most appropriate treatment will improve the quality of life of affected individuals, while at the same time relieving pressure on the healthcare system"

"Businesses have realised that advanced analytics and rapid innovation is the key to building competitive advantage in a data-driven world, so where billion row queries that took hours were once acceptable, the market now demands trillions of rows and speed-of-thought results. Aside from performance and scale, database technology needs to be built with the future of the connected world in mind – providing flexibility and cost predictability, even as the demands for big data continues to grow."

"In these extraordinary times, this investment gives us the capacity to increase our sales and business development resources and sell more into international markets where we have already won prestigious contracts. It also enables us to capitalise on multi-year procurement opportunities. We’re pleased to have our existing investors follow on in this round, and excited to see what we can achieve with their continued support."

"There is a clear market need for high-quality protein reagents, especially for applications in stem cell biology and organoid research. Qkine has both a compelling technology to meet this need and a highly experienced management team to drive the growth of the business."

"The increasing incidence of debilitating ophthalmic diseases brings morbidity and economic cost, and we are pleased to announce our seed funding today to tackle these urgent issues. We thank our investors UKI2S, LifeArc and Parkwalk for their support, and look forward to working with them to build Ikarovec into a leading gene therapy company."

"Following the recent announcement of Dr. Jane Osbourn, OBE, as Chair of Mogrify, I am delighted we have been able to make an initial close of this fundraising round, with the backing of both existing and new investors. Due to the significant interest, we have been able to secure this growth-funding without engaging in a protracted and distracting fund-raising process. Having now raised over $20 million, we can focus on delivery of our business strategy with the support of an aligned investor group. We will continue to engage with high-caliber investors with computational biology and cell therapy domain expertise as part of our on-going investor relations and capital markets strategy."

"Coronary heart disease is endemic worldwide but far too often the decision to implant a stent is based on sub-optimal information. Our technology addresses the ‘grey zone’ of patients where the requirement for a stent is currently difficult to determine. By using advanced optical sensing technology, we hope to significantly improve the accuracy of current treatments, saving healthcare costs and preventing unnecessary operations for patients that could be treated with medicines."

"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."

"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."

"This funding marks the start of the next phase in Paragraf’s growth. I am extremely proud of the young team at Paragraf who have collectively delivered the early strategy milestones with great skill. This next phase will allow Paragraf to make these truly game-changing technologies a reality. Paragraf is continually seeking like-minded collaborative development, production and commercial partners to accelerate the delivery of the many exciting electronics technology opportunities graphene has to offer."

"We are delighted to have secured this latest round of growth funding, which has demonstrated continued support from existing investors and will enable us to take full advantage of the global growth opportunities we are presented with. Our range of market leading radiation detection technologies provide real world solutions to real world challenges and expanding our operations in the US is a key tenet of our growth strategy."

"Commercial insurance underwriting is inaccurate and inefficient,"